---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-004172"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-01-17T23:59:59+00:00"
generated_at: "2026-06-06T22:27:26.104181+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma enters $1M convertible note financing with Lind Global Fund II

## Summary
- Issued $1,000,000 secured convertible note to Lind Global Fund II at $833,333 purchase price (16.7% OID).
- Conversion price: lesser of $3.50 fixed or 90% of avg three lowest VWAPs over 20 days; fixed for first 180 days.
- Warrant for 1,000,000 shares at $2.00/share exercises cashless under certain conditions; 5-year term.
- Company grants Lind 18-month right of first refusal for up to 10% of any subsequent equity financing.
- Allele Capital Partners and Wilmington Capital Securities acted as placement agents; received 25,000-share warrant.

## SEC filing metadata
- accession: 0001213900-24-004172
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-01-17T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/0001213900-24-004172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/ea191664-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-004172
- JSON: https://secwatch.observer/filing/0001213900-24-004172.json
- Plain text: https://secwatch.observer/filing/0001213900-24-004172.txt

## Key facts
- Material Agreements
  ABVC BIOPHARMA, INC. entered into Securities Purchase Agreement with Lind Global Fund II, LP valued at $1,000,000 (effective 2024-01-17).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Lind Global Fund II, LP
  - Value: $1,000,000
  - Effective: 2024-01-17
  source text: On January 17, 2024, ABVC BioPharma, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Lind Global Fund II, LP (“ Lind ”), pursuant to which the Company issued Lind a secured, convertible note in the principal amount of $1,000,000 (the “ Offering ”), for a purchase price of $833,333
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/0001213900-24-004172-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.